Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Community First Bancshares Inc (CFBI)

Community First Bancshares Inc (CFBI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 76,314
  • Shares Outstanding, K 7,571
  • Annual Sales, $ 16,640 K
  • Annual Income, $ 360 K
  • 60-Month Beta 0.62
  • Price/Sales 2.69
  • Price/Cash Flow 61.44
  • Price/Book 0.96
Trade CFBI with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.22
  • Most Recent Earnings N/A on N/A
  • Latest Earnings Date 11/11/20
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.50 +6.11%
on 12/21/20
10.18 -0.98%
on 01/20/21
+0.62 (+6.55%)
since 12/18/20
3-Month
7.10 +41.97%
on 11/02/20
10.18 -0.98%
on 01/20/21
+2.78 (+38.12%)
since 10/20/20
52-Week
5.36 +88.06%
on 04/02/20
12.00 -16.00%
on 01/21/20
-1.93 (-16.07%)
since 01/17/20

Most Recent Stories

More News
Can-Fite to Conduct Meetings at the BIO-Europe Spring Conference with Pharma Companies Interested in Licensing and Distributing Piclidenoson and Namodenoson

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, announced today...

CFBI : 10.08 (-0.30%)
CANF : 2.14 (+5.42%)
Can-Fite to Treat Decompensated Liver Cirrhosis Patients with Namodenoson Under Compassionate Use Setting

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, announced today...

CFBI : 10.08 (-0.30%)
CANF : 2.14 (+5.42%)
Novel Approach to Treating Advanced Liver Cancer with Namodenoson Published in Leading Scientific Journal: 12-Month Survival of 44% for Namodenoson vs. 18% for Placebo

Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today...

CFBI : 10.08 (-0.30%)
CANF : 2.14 (+5.42%)
Can-Fite Updates: Namodenoson Increases Survival for the Most Severe Patients with Advanced Liver Cancer

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today...

CANF : 2.14 (+5.42%)
CFBI : 10.08 (-0.30%)
Can-Fite’s Partner Vetbiolix is Heading into a European Multicentric Clinical Trial with Piclidenoson for the Treatment of Pets’ Osteoarthritis

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today...

CANF : 2.14 (+5.42%)
CFBI : 10.08 (-0.30%)
Can-Fite Reports Third Quarter 2022 Financial Results & Provides Clinical Update

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today...

CANF : 2.14 (+5.42%)
CFBI : 10.08 (-0.30%)
Can-Fite: Positive New Data from it’s Phase III Psoriasis Study will be Presented Today at an Industry Expert Summit in Boston

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, announced...

CANF : 2.14 (+5.42%)
CFBI : 10.08 (-0.30%)
Can-Fite: Findings Showing the Complete Clearance of Cancer in Patient Treated With Namodenoson Will Be Presented at the AASLD Liver Meeting®

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, announced...

CANF : 2.14 (+5.42%)
CFBI : 10.08 (-0.30%)
Can-Fite to Present its Phase IIb NASH Drug Candidate Namodenoson at Upcoming Conference

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, announced...

CANF : 2.14 (+5.42%)
CFBI : 10.08 (-0.30%)
Can-Fite: New Phase III Psoriasis Data Showing Superior Safety & Improved Efficacy Presented by KOL Dr. Papp at the 31st European Academy of Dermatology

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, announced...

CANF : 2.14 (+5.42%)
CFBI : 10.08 (-0.30%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Community First Bancshares, Inc. is a bank holding company. It offer financial products and services which includes savings accounts, personal and business loans, debit and credit cards, letter of credit, certificate of deposits, mortgages, equipment financing, cash management and online banking. Community...

See More

Key Turning Points

3rd Resistance Point 10.34
2nd Resistance Point 10.26
1st Resistance Point 10.17
Last Price 10.08
1st Support Level 10.00
2nd Support Level 9.92
3rd Support Level 9.83

See More

52-Week High 12.00
Last Price 10.08
Fibonacci 61.8% 9.46
Fibonacci 50% 8.68
Fibonacci 38.2% 7.90
52-Week Low 5.36

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar